Abu dhabi: M42's National Reference Laboratory (NRL) has collaborated with digital pathology innovator Qritive to introduce advanced AI-powered prostate cancer diagnostics in the UAE. The deployment marks a significant advancement in how prostate cancer is detected and diagnosed in the UAE, reinforcing NRL's commitment to harnessing advanced technology to deliver faster, more accurate, and more consistent patient care.
According to Emirates News Agency, as pathology enters a new era of digital transformation, AI is becoming an increasingly important enabler of diagnostic excellence. At the core of this is Qritive's AI Prostate module, which digitally analyses tissue samples, highlights areas of concern, and provides structured insights to support faster, more consistent cancer detection and grading.
Integrated into NRL's diagnostic workflow at Cleveland Clinic Abu Dhabi, the AI solution is expected to support pathologists in identifying subtle disease patterns, standardise interpretation, and improve workflow efficiency, ultimately accelerating clinical decision-making for patients with cancer.
Qritive's prostate AI solution is designed to support pathologists in detecting malignant glands, identifying tumour architecture, and enabling standardised grading in line with the internationally recognised International Society of Urological Pathology (ISUP) criteria. The platform can also assist in characterising Gleason patterns, quantifying tumour burden, and highlighting suspicious regions on digital pathology slides, providing an additional layer of analytical support during case review.
Dr. Laila Abdel Wareth, CEO of Diagnostics at M42, emphasised the transformative potential of AI in pathology, stating that it enhances diagnostic precision, reduces variability, and empowers specialists to focus on complex clinical decisions. She highlighted the promise of technologies like Qritive's in improving grading accuracy, which directly influences treatment pathways in diseases such as prostate cancer.
Dr. Shweta Narang, Executive Director Medical and Commercial Operations at NRL, underscored the efficiency benefits of AI-enabled prostate diagnostics, stating that it helps healthcare providers manage rising demand while offering patients and clinicians clarity at critical stages of care. This milestone reflects NRL's commitment to advancing diagnostics and improving patient outcomes across the UAE.
Bruno Occhipinti, CEO of Qritive, expressed pride in collaborating with NRL, acknowledging their shared belief in AI's role in augmenting pathologist capacity amidst rising disease occurrences. He noted that this deployment represents a shared commitment to delivering high-quality, technology-enabled, and compassionate care for the region.